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Summary Introduction
Hypokalemic period.c paralyse (hypoPP) is an autosomal ?fxiod]c j ^  nondystrophic myotonia constitute
dominant disorder belonging to a group o f muscle diseases a particular of muscle diseases known to impHcate
involving the abnormal function of ion channels. This an a b n o r m a l  f u n c t i o n  0 f  ion channels; the “ muscle ion- 
group of muscle diseases also comprises hyperkalemic peri- diseases >, Acute and reversible attacks of muscle
odic paralysis and paramyotonia congenita, both sodium- weaknfiSS are due t0 depolarization of the sarcolemmal
cianne iseases, an myotonia congenita, a c i  011 e- membrane and are the hallmarks of both hypokalemic and
channel disorder. HypoPP is characterized by acute attacks * i t *  • i • \>r. . • i £ it * i i j  hyperkalemic periodic paralysis. Myotonia is caused by
of muscle weakness concomitant w ith  a fall in blood potas­
sium levels. We recently localized the hypoPP locus (hy- 
poPPl) to chromosome lq31-32, in an interval where the 
a l  subunit of the dihydropyridine receptor calcium chan­
nel (CACNL1A3) also maps. Subsequently, deleterious 
mutations in the voltage-sensor segment S4 were found, 
establishing the dihydropyridine receptor CACNLI A3 as 
the causative gene for hypoPP. In this paper, we report 
the study of 16 hypoPP families of Caucasian origin. 
We found only two m utations— Arg528His and
that cosegregated with hypoPP, each in half 
of the families. Analysis of the clinical characteristics of 
both groups of families demonstrated that incomplete pen- 
ctrancc is a distinctive feature of the Arg528His mutation.
hyperexcitability of the sarcolemmal membrane and char­
acterizes both paramyotonia congenita and myotonia co n ­
genita. All these muscle disorders are hereditary conditions 
of autosomal dominant inheritance, except myotonia con­
genita, which is transmitted with both autosomal recessive 
and dominant inheritance. A candidate-gene approach has 
revealed that hyperkalemic periodic paralysis and para­
myotonia congenita are caused by allelic mutations of the 
muscle sodium-channel SCN4A (Fontaine et al. 1990; Pta- 
cek et al. 1991, 1992; Rojas et al. 1991; McClatchey et al. 
1992/;), as are their clinical variants normokalemic periodic 
paralysis and sodium-channel myotonia (Heine et al. 1993;
Plassart et al. 1994b; Ptacelc et a l  1994b), Interspecies
Using dinucleotide repeats contained within o r close to the ^ t v a a o n  of syntetic loci determined by analogy with a
dihydropyridine receptor gene, in conjunction with evi- n™ me model of hu™an my ° toma Perm,ttecl
dence of a dc novo A rgl239H is mutation, we show that of die S ^ t i c  anomalies causing myotonia congenita: allelic
a founder effect is unlikely to account for the two predomi-
nant mutations.
mutations of the muscle chloride-channel CLCN1, re­
sulting in a null allele in the recessive form of the disease 
and in a dominant negative effect of the mutated allele in 
myotonia congenita with autosomal dominant inheritance 
(Koch et al. 1992; George et al. 1993).
The most recent member to be added to the muscle ion- 
Received September 8, 1994; accepted for publication October 26, channel diseases is hypokalemic periodic paralysis (hypoPP;
MIM 170400 [McICusick 1990]). In this disease, acute at­
tacks of muscle weakness are accompanied by a fall in 
blood potassium levels. Precipitating factors include both 
the ingestion of a meal rich in carbohydrates and rest after
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exercise. The onset of the disease is usually in the 2d decade, Mutations of the a  I Subunit of the Dihydropyridine-Sensitive 
and penetrance is incomplete in women. In the 4th or 5 th Calcium-Channel CACNLI A3
decade of life, a vacuolar myopathy appears, which causes Two mutations of the dihydropyridine receptor were
permanent muscle weakness. Recently, by a combined can- found in our '16 families: the Arg528His and the 
didate-gene and genomewide search, the hypoPP locus was Argl23.9His mutations (Jurkat-Rott et al. 1994; Ptacek et 
localized to chromosome lq31-32 and termed “hypoPPl ” 1994a). The first one causes the loss of a Bbvl restriction 
(Fontaine et ah 1994). In our initial study, hypoPPl was site, and the latter causes the appearance of a NlalU restric- 
colocalized with the calcium-channel CACNLI A3, also tjon site, allowing rapid screening by PCR and restriction- 
known as the a l  subunit of the dihydropyridine receptor, enzyme digestion as shown in figure 1. The sequencing 
rendering this gene a plausible location for the hypoPPl ()f the mutation was performed for at least one affected 
gene defect (Fontaine et al, 1994),
The dihydropyridine receptor belongs to the family of 
“voltage-gated ion channels” and shares with potassium, 
sodium, and calcium channels a common structure con­
sisting of six transmembrane segments organized in do­
mains (Catterall 1993). The a l  subunit of the dihydropyri-
individual per family.
Genetic Analysis
The frequencies of dinudeotide-repeat alleles were deter­
mined by typing 82 unrelated and unaffected Caucasian 
individuals married to members of the studied families. The
dine receptor is composed of four domains (Tambe et al. e*Pected frequencies of the dinudeotide-repeat alleles and 
1987). Deleterious mutations have been demonstrated in tho >™Plotypes o f the studied families were calculated
the voltage-sensor segment S4 of the dihydropyridine reeep from the frequencies observed in controls. Expected and
tor, establishing CACNLI A3 as the causative gene for hy- obsc'7ecl allele ant! f lu e n c ie s  m the affected 
poPPl (Jurkat-Rott et al. 1994; Ptacek et al. 1994*). In Population T  re u«ng * *  f  test (with the Yates 
this study of 16 hypoPP families of Caucasian origin, we correction when necessary). The relative risk of disease con­
found only two different mutations responsible for the dis- <;clTecl >  each aliele was calculated with Woolf’s (1955)
ease. We report the genotype/phenotype correlations for
both mutations, as well as the haplotypes segregating with Results
both mutations analyzed by flanking markets of the hy- Arg528His and Arg 1239His Mutations of the Dihydropyridine
poPPl locus and intragenic dmucleotide repeats contained Recept0/. as the Predominant Mutations Causing hypoPP
within the dihydropyridine receptor gene.
Patients and Methods
Patients
Sixteen Caucasian families displaying hypoPP linked to 
the hypoPPl locus on chromosome lq31-32 were studied. 
Families 9, 15, and 1 already have been described by Fon­
taine et al, (1994), as families A, B, and C, respectively; 
families 5 and 6 have been referred to as families 15 and 
1.6 by Jurkat-Rott et al, (1994). Family 7 also has been 
analyzed elsewhere (Links et al. 1994).
DNA Analysis
Blood samples were collected from all consenting family 
members and Caucasian controls. The protocol of the study 
was approved by the ethics committee of La Salpetrière 
Hospital in 1993 and conformed to the Helsinki Conven­
tion. DNA extraction was performed by proteinase K lysis, 
phenol-chloroform extraction, and salt precipitation as de­
scribed elsewhere (Gusella 1986). The following dinucleo­
tide repeats were typed in all families and controls: CAC­
NLI A3 (Gregg et al. 1993) and D1S1723 and DIS 1726 
(Jurkat-Rott et al. 1994). Genotyping was performed by
By restriction-enzyme and sequence analysis, the 
Arg528His and the Argl239His mutations were each 
found in 8 of 16 Caucasian families linked to chromosome 
1. The mutations cosegregated with hypoPP in each family 
(fig. I). A Japanese family with hypoPP also carried the 
Arg528His mutation (data not shown).
We observed a de novo Argl239His mutation in family 
10 (fig. IB). Individual 10-3, an affected 36-year-old man, 
transmitted the disease to his 10-year-old son (10-5) but 
not to his daughter (10-6), His parents, 1.0-1 and 10-2, 
were both 72 years old and normal according to both 
medical history and clinical examination. As shown in fig­
ure I H, 10-3 and 10-5 displayed the restriction pattern of 
the ArgI239H is mutation, whereas in 10-1, '10-2, and 10- 
6 the restriction pattern was normal. By reconstruction of
the haplotypes for DLSI726, CACNLI A3, and D1SI723, 
the affected individual 10-3 was shown to have inherited 
the diseased hapfotype from his mother, 10-2 (data not 
shown). Nonpaternity was ruled out by typing 10 diiuicleo- 
tide repeats (data not shown). The mutation, therefore, 
arose de novo in individual 10-3, from a maternally inher­
ited chromosome. We did not find evidence of a de novo 
Arg528His mutation in the families that we studied.
the PCR-blotting technique described by Hazan et al. Incomplete Penetrance in Women as a Distinctive Feature of the 
(1992). The dinudeotide-repeat alleles were numbered ac- Arg528His Mutation
cording to decreasing size on the same gel, to allow compar­
ison between families (table 1 ).
Are there clinical particularities associated with each mu­
tation? In order to answer this question, we divided the 16
37 6 Am . J. I iw n . Genet. 56:374-18(1 J99S
Table I
H apio types Segregating with C A C N L IA 3  Mutations in 16 Caucasian Families with hypoPP
G r o u p  a n d  
F a m i l y D1S1726
H a p l .o t y p u
CACNL1A3 DISI 723 NUCLHOTIDF. M u t a t i o n D o m a i n
A:
B:
1 ,, 4 6 5 G1583A Arg528His IIS 4
3 8 2 G l 583A Arg528His IIS4
1 ■ . 4 4 4 G l 583A Arg528I-ILs IIS4
4 , ,, 4 4 6 G 1583A Arg528His IIS4
s .... 3 6 6 G l 583A Arg528His IIS 4
4 1 4 G1583A At’g528His IIS 4
7 .... 8 6 G l 583A Arg528His IIS 4
8 .... 7 2 6 G1583A Arg528His I IS 4
9 7 8 6 G3716A Argl239His IVS4
10 ... 4 8 6 G3716A Argl239His I VS 4
II , 4 4 5 G3716A Ai:g'1239His IVS4
1? 4 2 6 G3716A Argl239His I VS 4
n  , 3 6 5 G3716A Argl239His IVS4
14 ... y 8 4 G3716A Argl239His IVS4
H  , 4 8 4 G3716A Arg1239His IVS4
16 ... 4 8 8 G3716A Argl239His IVS4
families into two groups, A and B, corresponding, respec- were as follows: allele 1 , .024; allele 2, .354; allele 3, .049;
tively, to families 1 -8  with the Arg528His mutation and allele 4, .037; allele 5, .024; allele 6, .207; allele 7, .012;
families 9 -1 6  with the A rgl239H is mutation. As already and allele 8, .293. D1S1726 and DIS'1723 are separated
described for hypoPP, we found male predominance by a genetic distance of 0 cM, as determined in the eight
(maleifemale sex ratio 1,23:1), which was not significantly CEPH families used to construct the Genethon map (Gya-
different in groups A and B (data not shown). Interestingly, 
incomplete penetrance in women was observed only in 
group A. The estimated penetrance in females was 84% 
and 100% in groups A and B, respectively (%z =  7.37; P
pay et al. 1994; Jurkat-Rott et al. 1994). The physical 
distance between D IS ’1726 and D1S1723 is unknown. The 
haplotype 5-8 for D1S1726-CACNLI A3 is in linkage dis­
equilibrium in the control population (frequency observed,
<  .01). An example of incomplete penetrance is shown in 4.7%; frequency expected, 1%; %“ = 5.6; P <  .05), an 
family 6, where an unaffected woman (1-3) transmitted the observation consistent with the close genetic linkage of the
two markers. CACNL1A3 allele 4 was significantly more 
frequent in hypoPP patients (frequency of allele 4, 18.75%; 
relative risk, 2.72; %2 = 6.4; P <  .05). An increase in the
disease to her children (fig. 2). One of her symptom-free 
daughters (II-6) transmitted hypoPP to her children (fig. 2), 
The Arg528His mutation was identified in these two
women and in the asymptomatic daughter of the second frequency of allele 4 of marker 1) LS I 726 was found in
woman (III-7) (fig. 2). In family 6, none of the females hypoPP families (frequency of allele 4, 56%), compared
carrying the mutation suffered from hypoPP. No case of with controls (frequency of allele 4, 25%) (relative risk,
incomplete penetrance in males could be demonstrated. 2.05; %z = 6.7; P =  .0 1). The frequency of allele 6 of marker
The mean age at onset was similar in both groups (14,8 D1S1723 was increased in the 16 families, compared with
±  1.3 years and 12.7 ±  2.68 years in groups A and B, 
respectively), as were the precipitating factors. The propor-
controls (frequency 43,8% , vs, 17.9% in controls; relative 
risk, 2.1; X  =  5.61; P <  .05). However, for each marker,
tion of patients presenting clinical symptoms of myopathy we did not observe a significant difference in the frequencies
was also similar in groups A and B (28.3%) and 28.6% of 
the patients, respectively; %2 -  .002; NS).
No Evidence for a Founder Effect
We  typed CACNL1A3 and the flanking markers of the 
hypoPP 1 locus, DLSI726 and D1S1723, in the 16 families 
and in unrelated individuals of Caucasian origin. The fre­
quencies of CACNL1A3 alleles in the control population
of these particular alleles in groups A and B. The haplotypes 
segregating with the disease for the flanking markers 
DLS1726 and D1S1723 of the hypoPP 1 locus and for 
CACNL1A3 were reconstructed in the 16 families (table I). 
Haplotypes segregating with the mutations were different. 
There was no haplotype preferentially associated with ei­
ther mutation. In conclusion, our data do not support a 
founder effect in
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A Discussion
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Eight of 16 Caucasian families with hypoPP displayed 
the Arg528His mutation, and the other 8 displayed the 
Argl239His mutation, of CACNL1A3 (Jurkat-Rott et al. 
1994; Ptacek et al. 1994a), The Argl239His and the 
Arg528His mutations were originally reported in 10 and 
9 families, respectively, but no information was given on 
the haplotypes segregating with either mutation (Jurkat- 
Rott et al. 1994; Ptacek et al. 1994#). A rarer mutation 
has also been described, by Ptacek et al. (1994#), at position 
1239— the substitution of an arginine by a glycine— which 
was not found in our families. In addition to the families 
presented in the present paper, three other hypoPP families 
of Caucasian origin were studied. One of these families, 
also linked to chromosome lq31~32, does not show any 
of the known mutations of the a l  subunit of the dihydro­
pyridine receptor (data not shown), suggesting that other 
mutations of the calcium channel remain to be discovered. 
The other two are not linked to the hypoPPl locus. One 
is of French ancestry (Plassart et al. 1994#), and the other is 
of Portuguese origin (data not shown), establishing genetic 
heterogeneity in hypoPP (Plassart et al. 1994a). Taken to­
gether, these results indicate that the hypoPPl/CACNLlA3 
locus on chromosome 1 is a major locus for hypoPP and 
that Arg528His and Argl239His are predominant muta­
tions, at least in the Caucasian population. Interestingly, a 
Japanese family with hypoPP also displays the Arg528His 
mutation, suggesting that it might also cause hypoPP in 
families with other ethnic backgrounds. The two mutations 
can easily be detected by PCR amplification of genomic 
DNA and restriction-enzyme analysis, enabling molecular 
diagnosis.
How do these data compare with those for other muscle 
ion-channel diseases? The Thr704Met and the M etl592- 
Val SCN4A mutations account for ~ 7 5% and ~ 2 5%, 
respectively, of hyperkalemic periodic paralysis families 
(Feero et al. 1993; Ptacek et al. 1993). In the French popula­
tion, the Thr704Met mutation was die only SCN4A muta­
tion observed in families with hyperkalemic periodic paral-
ArgI239His jjj
unaffected 5'-CGC CTG 'ITC C G I GTC ATGTAGG CTG ATC-3 ‘
Argl239
Nla III Nla HI
affected 5-CGC CTGTTC CAT ^TC ATGTAGG CTG ATC-3'
His 1239
Figure I Rapid screening of di hydropyridine receptor, CAC- 
NL1A3, mutations causing hypoPP using PCR amplification of genomic 
DNA and restriction enzyme analysis: identification of a de novo 
Argl239His mutation. The wild-type and the mutant dihydropyridine 
receptor gene sequences are shown for the Arg528His (.A) and the 
Argl239His (B) mutations; the restriction-enzyme sites that are modified
by the mutations are indicated—the Arg528His mutation abolishes a 
Bbvl site, and the Arg'1239His mutation creates a new N/tfIII site. A, 
Pedigree of a family with the Arg528His mutation and the corresponding 
polyacrylamide gel stained by ethidium bromide, showing PCR-amplified 
genomic DNA fragments after digestion with Bbvl. PCR amplification 
and digestion in normal individuals (1-3) produce two bands (53 bp and 
43 bp); PCR products of heterozygous affected individuals (4 and 5) 
contain a third, undigested band of 96 bp, resulting from the disappear­
ance of a Bbvl site. B, Pedigree of family 10 and the corresponding 
Southern blot obtained by transfer of a polyacrylamide gel, showing PCR- 
amplified genomic DNA fragments after digestion with Nlctlll. PCR prod­
ucts of normal individuals (10-1, 10-2, 10-4, and 10-6) have two bands, 
of 63 bp and 48 bp, whereas PCR products of heterozygous affected 
patients (10-3 and 10-5) have a third band, of 43 bp, resulting from a 
new NlalU site in the 48-bp fragment.
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family 6, this observation is important for genetic counsel­
ing. These data also raise a fundamental question: Why do 
women carrying the Arg528His mutation not express the 
disease? Dihydropyridine receptors are located in the tubu­
lar system, which might be under hormonal control. A 
regulation of this type was recently demonstrated in a 
mammalian muscle-cell line expressing androgen receptors, 
where voltage-gated sodium currents decreased, through a 
posttranscriptional mechanism, when the cells were treated 
by androgens or overexpressed the androgen receptor 
(Tabb et al, 1994). Alternatively, the other subunits of the 
dihydropyridine receptor might modulate the phenotypic 
expression of the a l  subunit, as already demonstrated for 
the P subunit (Lory et al. 1991; Isom et al, 1994), It is also
possible that the dihydropyridine receptor might interact 
with other proteins, such as the ryanodine receptor, to 
induce a proper excitation-contraction coupling. These 
questions should be addressed by ongoing in vitro expres­
sion studies of the mutated dihydropyridine receptor. 
The role of a calcium channel in the occurrence of the 
vacuolar myopathy should also be clarified by these expres­
sion studies.
ysis, despite the absence of a founder effect demonstrated Finally, does a founder effect explain the origin of the 
by the analysis of intragenic dinucleotide repeats contained two major mutations in hypoPP? When haplotypes were 
within SCN4A (Plassart et al. 19946). The diversity of reconstructed for DIS 1723, CACNL1A3, and D1S1726, 
SCN4A mutations already described is more pronounced no common haplotypes were found in patients sharing the 
for paramyotonia congenita than for hyperkalemic periodic same mutation. Mutations in dinucleotide repeats consist
F i g u r e  2 Family with the Arg528His mutation showing incom­
plete penetrance in women. Clinically affected and unaffected individuals 
in family 6 are represented by blackened and unblackened symbols, re­
spectively. Genotypes are indicated for markers D ISI726, CACNLIA3, 
and DIS1723. The baplotypc segregating with hypoPP is boxed, Haplo­
types between brackets are inferred. Recombination events are indicated 
by arrowheads. The identification numbers of individuals carrying the 
Arg528His mutation are circled. In this family, three women (1-3, II-6, 
and III-7) carry the mutation, but none are clinically affected.
paralysis (Ptacek et al. 1993). Several SCN4A mutations 
occur more frequently than others, however: for example, 
the Thrl313Met mutation was observed in five of six fami-
of an addition or deletion of a single base pair, at a rate 
estimated to be 1/103 (Weissenbach et al. 1992; Weber 
and Wong 1993). The dinucleotide-repeat mutation rate is
lies in the French population. In the German population, therefore insufficient, by itself, to explain the variety of
both the Arg'1448Cys and the Argl448His mutations of haplotypes shown by hypoPP patients. Moreover, both the
the sodium-channel SCN4A were found (Meyer-Kleine et demonstration of a de novo Argl239His mutation, as al-
ah 1994). A founder effect was demonstrated only for fami- ready reported (Ptacek et al. 1994tf), and the finding of
lies originating in the Ravensberg area (Meyer-Kleine et al. 
1994). The only study published so far with a large number 
of families with autosomal recessive myotonia congenita 
found the same mutation in the chloride-channel CLCN1
a Arg528His mutation in a family of a different ethnic 
background (Japanese) do not support a founder effect. 
Similarly, no founder effect was demonstrated in hyperka­
lemic periodic paralysis and paramyotonia congenita, de­
in only 15% of the families studied (Koch et al, 1993). spite the recurrence of some of the SGN4A mutations
(Wang et al. 1993; Meyer-Kleine et al. 1994; Plassart et 
al. I0C1
Why do recurrent mutations occur within the same gene?
Because of the lack of studies with large numbers of families 
affected by myotonia congenita, it is still impossible to 
draw definitive conclusions regarding the predominance of
a particular CLCN'l mutation. It is interesting to note that, From the studies of the sodium-channel SGN4A, we know
in the case of malignant-hypeithermia syndrome, genetic that both conservative and nonconservative nucleotide
linkage to and a mutation in the ryanodine receptor RYR1 changes may occur in the coding sequence of the gene
were published several years before a particular mutation (George et al. 1992; McClatchey et al. 1992a; Wang et al.
was found that accounted for a significant number of cases 1992, 1993; Heine et al. 1993). Some of these nucleotide
(Quane et al. 1994). changes may not have biological significance and may be
Are there clinical characteristics preferentially associated considered as benign polymorphisms, particularly when
with either mutation in hypoPP? W e did not find a signifi- they are conservative in term of amino acids. The role of
cant difference regarding the age at onset, the number of nonconservative nucleotide changes that do not segregate
acute attacks, the precipitating factors, and the proportion with the disease has not been investigated, however, by in
of patients presenting a vacuolar myopathy, Interestingly, vitro expression of mutated channels (Cannon et al. 1993;
incomplete penetrance for women was found only in the Cummins et ah 1993; Chahine et al. 1994). Since the se-
families with the Arg528His mutation. As illustrated by quence of ion channels is well conserved throughout evolu-
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Cion, nonconservative nucleotide changes may modulate the 
(abnormal) properties of the mutated channel, contributing 
to the well-known intrafamilial clinical variability in muscle 
ion-channel diseases. The predominance of certain muta­
tions might be due to an observation bias caused by the 
phenotype observed, i.e., hypoPP in this case. Conse­
quently, other mutations of the a l  subunit of the dihydro­
pyridine receptor might be associated with an as yet un­
linked phenotype, as with hyperkalemic periodic paralysis 
and paramyotonia congenita and the sodium-channel gene 
SCN4A. It should be recalled that linkage of the dihydro­
pyridine receptor to hypoPP was unexpected (Fontaine et 
al 1994). Both of the predominant: mutations in hypoPP 
result in an amino acid change of an arginine in the voltage 
sensor of the calcium channel, which belongs to a ring of 
positive charges shared by all the members of the voltage- 
gated ion-channel family (potassium, sodium, and cal­
cium channels) that might play a crucial role in the 
voltage-dependent calcium flux and excitation-contraction 
coupling.
In conclusion, our study of 16 families with hypoPP 
demonstrates the predominance of two mutations in CAC-
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